The immunogenicity of protein therapeutics has so far proven to be difficult to predict in patients, with many biologics inducing undesirable immune responses that are directed towards the therapeutic resulting in reduced efficacy, anaphylaxis and occasionally life threatening autoimmunity.  The most common effect of administrating an immunogenic protein therapeutic is the development of a high affinity anti-therapeutic antibody response.  Furthermore, it is clear from clinical studies that protein therapeutics that are derived from endogenous human proteins are capable of stimulating undesirable immune responses in patients, and as a consequence, the prediction and reduction of immunogenicity has been the focus of intense research.  This review will outline the principle causes of the immunogenicity in protein therapeutics, and describe the development of pre-clinical models that can be used to aid in the prediction of the immunogenic potential of novel protein therapeutics prior to administration in man.